Novartis said an important new drug for treating heart failure has been granted an accelerated review by European authorities, improving its chances of approval in Europe next year.
via WSJ.com: US Business http://ift.tt/1xZ2JeE
via WSJ.com: US Business http://ift.tt/1xZ2JeE
Nessun commento:
Posta un commento